Home Cart Sign in  
Chemical Structure| 149-30-4 Chemical Structure| 149-30-4

Structure of 2-Mercaptobenzothiazole
CAS No.: 149-30-4

Chemical Structure| 149-30-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

2-Mercaptobenzothiazole is an endogenous metabolite.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Ahmed A. Elbatrawy ; Taiwo A. Ademoye ; Heba Alnakhala ; Arati Tripathi ; Ashique Zami ; Raluca Ostafe , et al.

Abstract: Tau and aggregates are the main histopathological hallmarks present in Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative disorders. Intraneuronal hyperphosphorylated tau accumulation is significantly connected to the degree of cognitive impairment in AD patients. In particular, the longest 2N4R tau isoform has a propensity to rapidly form oligomers and mature fibrils. On the other hand, misfolding of (α-syn) is the characteristic feature in PD and dementia with Lewy bodies (DLB). There is a strong crosstalk between the two prone-to-aggregation proteins as they coprecipitated in some brains of AD, PD, and DLB patients. Simultaneous targeting of both proteinaceous oligomers and aggregates is still challenging. Here, we rationally designed and synthesized benzothiazole- and indole-based compounds using the structural hybridization strategy between the benzothiazole N744 cyanine dye and the diphenyl pyrazole that showed anti-aggregation activity towards 2N4R tau and α-syn, respectively. The anti-aggregation effect of the prepared compounds was monitored using the thioflavin-T (ThT) fluorescence assay, while transmission electron microscopy (TEM) was employed to detect fibrils upon the completion of a time-course study with the assay. Moreover, the photo-induced crosslinking of unmodified protein (PICUP) assay was used to determine the formation of oligomers. Specifically, compounds 46 and 48 demonstrated the highest anti-aggregation activity by decreasing the fluorescence to 4.0 and 14.8%, respectively, against α-syn. Although no noticeable effect on 2N4R tau oligomers, 46 showed promising anti-oligomer activity against α-syn. Both compounds induced a significantly high anti-aggregation effect against the two protein fibrils as visualized by TEM. Moreover, compound 48 remarkably inhibited α-syn inclusion and cell confluence using M17D cells. Collectively, compounds 46 and 48 could serve as a basic structure for further optimization to develop clinically active AD and PD disease-modifying agents.

Keywords: Alzheimer’s disease ; Parkinson’s disease ; Alpha-synuclein ; Tau isoforms ; Anti-oligomer agents

Purchased from AmBeed: ;

Alternative Products

Product Details of 2-Mercaptobenzothiazole

CAS No. :149-30-4
Formula : C7H5NS2
M.W : 167.25
SMILES Code : S=C1SC2=CC=CC=C2N1
MDL No. :MFCD00005781
InChI Key :YXIWHUQXZSMYRE-UHFFFAOYSA-N
Pubchem ID :697993

Safety of 2-Mercaptobenzothiazole

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H317-H350-H410
Precautionary Statements:P201-P273-P280-P308+P313-P333+P313-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.98mL

1.20mL

0.60mL

29.90mL

5.98mL

2.99mL

59.79mL

11.96mL

5.98mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories